Objective-Ischemic stroke is primarily attributable to thrombotic vascular occlusion. Elevated α2-antiplasmin (a2AP) levels correlate with increased stroke risk, but whether a2AP contributes to the pathogenesis of stroke is unknown. We examined how a2AP affects thrombosis, ischemic brain injury, and survival after experimental cerebral thromboembolism. Approach and Results-We evaluated the effects of a2AP on stroke outcomes in mice with increased, normal, or no circulating a2AP, as well as in mice given an a2AP-inactivating antibody. Higher a2AP levels were correlated with greater ischemic brain injury (r s =0.88, P<0.001), brain swelling (r s =0.82, P<0.001), and reduced middle cerebral artery thrombus dissolution (r s =−0.93, P<0.001). In contrast, a2AP deficiency enhanced thrombus dissolution, increased cerebral blood flow, reduced brain infarction, and decreased brain swelling. By comparison to tissue plasminogen activator (TPA), a2AP inactivation hours after thromboembolism still reduced brain infarction (P<0.001) and hemorrhage (P<0.05). Microvascular thrombosis, a process that enhances brain ischemia, was markedly reduced in a2AP-deficient or a2AP-inactivated mice compared with TPA-treated mice or mice with increased a2AP levels (all P<0.001). Matrix metalloproteinase-9 expression, which contributes to acute brain injury, was profoundly decreased in a2AP-deficient or a2AP-inactivated mice versus TPA-treated mice or mice with increased a2AP levels (all P<0.001). a2AP inactivation markedly reduced stroke mortality versus TPA (P<0.0001). Conclusions-a2AP has profound, dose-related effects on ischemic brain injury, swelling, hemorrhage, and survival after cerebral thromboembolism. By comparison to TPA, the protective effects of a2AP deficiency or inactivation seem to be mediated through reductions in microvascular thrombosis and matrix metalloproteinase-9 expression. (Arterioscler Thromb Vasc Biol. 2014;34:2586-2593.) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
I schemic stroke affects 16.9 million people a year worldwide; it kills >5.4 million and disables millions of others. 1 Thrombotic obstruction of a cerebral artery may be triggered by thromboembolism, plaque rupture, atrial fibrillation, and other vascular events. 2, 3 Thrombotic occlusion initiates a cascade of events that cause neuronal cell death, matrix metalloproteinase (MMP) expression, breakdown of the blood brain barrier with brain swelling, hemorrhage, morbidity, and mortality. [2] [3] [4] [5] [6] Downstream from a thrombotic occlusion, ischemia may trigger the formation of microvascular thrombi that cause further reductions in blood flow, thereby enhancing blood brain barrier breakdown and ischemic tissue injury. 2, 3, 7 Clinical and experimental studies have demonstrated that tissue plasminogen activator (TPA), which initiates the conversion of plasminogen to plasmin, dissolves occlusive thrombi to improve outcomes after ischemic stroke. 4 However, there is little known in ischemic stroke about the role of molecules that regulate fibrinolysis downstream of TPA.
See accompanying editorial on page 2522
α2-Antiplasmin (a2AP) is a serine protease inhibitor that rapidly inhibits plasmin. 8 Most a2AP circulates in the blood, but a portion is crosslinked to fibrin by activated factor XIII during thrombus formation. 9 Recent studies have emphasized the role of thrombus-bound a2AP in regulating fibrinolysis or dissolution of pathological thrombi. 8, 9 Circulating a2AP inhibits circulating plasmin 100-to 1000-fold more efficiently than it inhibits fibrin or thrombus-bound plasmin; this has led some to propose that a primary role of circulating a2AP is to prevent bleeding by preventing the degradation of coagulation factors. 10, 11 However, recent studies indicate that high levels of circulating a2AP contribute to the failure of TPA therapy to dissolve thrombi and restore blood flow during ischemic stroke. [12] [13] [14] Moreover, genetic deletion of a2AP protects against ischemic brain injury induced by nonthrombotic permanent surgical ligation of the middle cerebral artery. 15, 16 Yet, within the neuronal and vascular compartments, a2AP and serpins that block TPA-initiated proteolytic pathways, such as the activation of MMP-9, may protect the brain by reducing cell death or neurotoxicity and may prevent bleeding complications. [17] [18] [19] [20] In this report, we investigated how circulating and thrombus-bound a2AP affect endogenous fibrinolysis, microvascular thrombosis, hemorrhage, brain injury, and other outcomes in an experimental thromboembolic model with translational relevance to human ischemic stroke. We find that thrombusbound a2AP modulates dissolution of the culprit thromboembolus, whereas circulating a2AP activity also has dynamic, deleterious effects on the development of microvascular thrombosis, MMP-9 expression, brain injury, hemorrhage, disability, and death after cerebral thromboembolism.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Dose-Related Effects of Circulating a2AP on Cerebral Thromboembolism
If a2AP activity directly contributes to the pathogenesis of stroke after thromboembolism, there should be a dose relationship between circulating levels of a2AP levels and outcomes. Three different experimental groups were examined: mice with increased levels of a2AP (achieved by intravenous supplementation), normal physiological a2AP levels (controls), or no circulating a2AP (a2AP −/− mice). 14 Intravenous supplementation increased blood a2AP levels by a median of 87.1 μg/mL (mean 79.3±14.3 μg/mL) in mice measured at the end of the experiment, which approximately doubled the a2AP levels found in normal mice. 21 Laser Doppler monitoring showed that middle cerebral artery (MCA) thromboembolism was associated with a marked drop in hemispheric blood flow to ≤20% of the initial baseline in all 3 groups as expected ( Figure 1A ). During the period of observation, there was a partial restoration of blood flow in a2AP −/− mice without circulating a2AP ( Figure 1A ), whereas hemispheric blood flow remained suppressed in mice with normal or increased levels of a2AP. Pathologically, there was evidence of proximal MCA occlusion ( Figure 1B) after thromboembolism, and the extent of brain infarction differed among the experimental groups as shown in TTC (2,3,5-triphenyltetrazolium chloride)-stained representative images of brain slices ( Figure 1B) .
When compared with mice with normal a2AP levels, mice with increased circulating levels of a2AP had larger areas of brain infarction ( Figure 1B and 1C; P<0.001). In contrast, mice without circulating a2AP had significant reductions in brain infarction by comparison to mice with normal ( Figure 1B and 1C ; P<0.01) or increased levels of a2AP ( Figure 1C ; P<0.001). There was a significant positive doserelated correlation between a2AP levels and brain infarction (Spearman's r=0.88; P<0.001).
In these experiments, we monitored the dissolution of 125 I-fibrin-labeled MCA thromboemboli (formed with pooled normal a2AP +/+ plasma) at 6 hours to assess brain injury during a time when thrombus dissolution was still dynamic, as suggested by our pilot studies. By comparison to mice with normal physiological levels of a2AP, mice with increased blood levels of a2AP had markedly decreased dissolution of the MCA thrombus ( Figure 1D ; P<0.01). In contrast, the dissolution of the MCA thrombus was accelerated in a2APdeficient versus mice with normal a2AP levels ( Figure 1D ; P<0.001) or versus mice with increased levels of circulating a2AP ( Figure 1D ; P<0.001). There was a significant negative correlation between the level of circulating a2AP and dissolution of the MCA thromboembolus (Spearman's r=−0.93; P<0.001). There was no significant relationship between a2AP levels and hemorrhage ( Figure 1E ).
Brain swelling is one of the more serious complications of proximal MCA thrombosis. Brain swelling was significantly greater in mice with high circulating levels of a2AP than with normal a2AP levels ( Figure 1F ; P<0.01) or a2AP-deficient mice ( Figure 1F ; P<0.001). There was a significant positive correlation between circulating a2AP levels and brain swelling (Spearman's r=0.82; P<0.001).
Effects of Thrombus-Bound a2AP on Outcomes in a2AP-Deficient Mice
The previous experiments had examined the effect of different levels of circulating a2AP on outcomes in mice with MCA thromboemboli made from plasma containing physiological levels of a2AP. To examine the potential additional contribution of thrombus-bound a2AP, we compared outcomes in a2AP-deficient mice with MCA thromboemboli made from plasma containing normal a2AP levels versus a2AP-deficient plasma. As expected, thromboemboli made from normal (a2AP +/+ ) plasma showed evidence of fibrin-crosslinked a2AP by immunoblotting using specific antipeptide or monoclonal antibodies ( Figure 1G ), whereas no crosslinked a2AP was seen in thromboemboli made from a2AP-deficient (a2AP −/− ) plasma ( Figure 1G ). In a2APdeficient mice, MCA thromboemboli containing normal levels of a2AP were more resistant to dissolution than a2AP-deficient thromboemboli, indicating that thrombus-bound a2AP affects endogenous fibrinolysis ( Figure 1H ; P<0.001). However, despite the differences in the extent of thrombus dissolution, there was no difference in brain infarction in mice with normal or a2AP-deficient thrombi ( Figure 1I ). In addition, the presence or absence of a2AP in the thromboembolus did not affect hemorrhage or brain swelling ( Figures 1J and 1K ).
Effects of a2AP During Prolonged Ischemia After Cerebral Thromboembolism
Taken together, these studies indicate that at the time of thromboembolism, levels of circulating a2AP have profound effects on stroke outcome. To examine whether a2AP continues to exert dynamic effects on the brain for hours after cerebral thromboembolism, mice were treated with a monoclonal
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α2-antiplasmin a2AP-I α2-antiplasmin inactivation MMP matrix metalloproteinase TPA tissue plasminogen activator antibody that inhibits a2AP (a2AP-I) and prevents the neutralization of plasmin. This a2AP-I bound specifically to mouse a2AP ( Figure 2A ) and accelerated the dissolution of mouse plasma clots in vitro ( Figure 2B ). 22 After MCA thromboembolism, laser Doppler monitoring showed a marked drop in hemispheric blood flow to ≤20% of the initial baseline in all 3 groups as expected ( Figure I in the online-only Data Supplement). Two and one half hours after cerebral thromboembolism, mice were treated with a standard dose of TPA 23 or with the a2AP-I. Plasma samples from mice receiving the a2AP-I confirmed that it significantly accelerated the dissolution of ex vivo clots ( Figure II in the online-only Data Supplement), and blood levels of the a2AP-I were 149±23 μg/mL (mean±standard error). By comparison to TPA, a2AP-I significantly reduced infarct size ( Figure 2C ; P<0.001).
Bederson neurological scores were better (ie, lower) in mice treated with a2AP-I versus TPA (median, 1 versus 3; P<0.02), indicating that a2AP-I treatment was associated with less neurological impairment. However, thrombus dissolution was significantly greater in TPA-treated mice than in those receiving a2AP-I ( Figure 2D ; P<0.0001). No significant differences were detected in brain swelling ( Figure 2E ), but there was significantly less brain hemorrhage in mice after a2AP-I administration than in mice treated with TPA ( Figure 2F ; P<0.05).
Effects of a2AP on the Development of Microvascular Thrombosis
Previous studies have shown that brain ischemia triggers the development of downstream microvascular thrombosis that enhances vascular obstruction, aggravates tissue ischemia, and contributes to breakdown of the blood brain barrier. 24 Therefore, we examined how circulating a2AP and TPA affected microvascular thrombosis. By comparison to control mice with normal levels of a2AP, microvascular thrombosis was more extensive in mice with high levels of circulating a2AP (Figure 3 , bar graph; P<0.001) or in mice treated with TPA ( Figure 3 , bar graph; P<0.001). The extent of microvascular thrombosis was comparable in mice with high circulating levels of a2AP and in TPAtreated mice (Figure 3 , bar graph; P=NS). In contrast, a2AP deficiency or a2AP-I markedly reduced microvascular thrombosis by comparison to mice with increased levels of circulating a2AP (Figure 3 , bar graph; P<0.001) and mice with treated with TPA ( Figure 3 
Circulating a2AP and MMP-9 Expression
The close link between thrombosis and inflammation in ischemic stroke has suggested that ischemic stroke is a thromboinflammatory disease. 25 MMP-9 expression is linked to the inflammatory response to ischemic injury and is notably increased after cerebral thromboembolism. 26 MMP-9 has been identified as a key acute mediator of breakdown of the blood brain barrier, hemorrhage, and brain edema in ischemic stroke. [27] [28] [29] In control mice with normal a2AP levels, cerebral thromboembolism was associated with higher levels of expression of MMP-9 versus shams (P<0.001, not shown). When compared with control mice with normal circulating levels of a2AP, mice with high levels of a2AP showed increased MMP-9 expression as assessed by quantitative immunofluorescence (Figure 4 , bar graph; P<0.05). MMP-9 expression was significantly lower in a2AP-deficient mice (P<0.001) or a2AP-I treated mice (P<0.01) by comparison to mice with elevated a2AP levels. Consistent with MMP-9 immunofluorescence and previous reports, in situ zymography activity seemed highest in the ischemic cortex of mice with increased a2AP levels, intermediate in mice with normal a2AP levels, and lowest in mice with a2AP-deficiency. ( Figure III 
Dynamic Effects of a2AP Activity Survival After Cerebral Thromboembolism
Proximal MCA stroke in humans is linked to extensive brain infarction and brain swelling that are associated with significant mortality. Because a2AP affected infarction and brain swelling after experimental thromboembolism, we examined whether a2AP-I after stroke onset may protect against mortality Figure 5A ). Mice treated with TPA also had significant mortality after thromboembolism ( Figure 5A ). Mice treated with a2AP-I, in the doses used in previous studies above, had significantly greater survival than control mice (P<0.05) or TPA-treated mice (P<0.001).
To determine whether the dose or the molecular form of the a2AP-I affected outcomes, we tested high dose a2AP in the form of an immunoglobulin (21.3 mg/kg) and as a Fab (9.5 mg/kg). All mice treated with high-dose a2AP-I in immunoglobulin or Fab form survived ( Figure 5A ). The survival of mice treated with high-dose a2AP-I was significantly greater than mice treated with low-dose a2AP-I (9.3 mg/kg; P<0.01), TPA treatment (P<0.0001), or control mice (P<0.0001).
Surviving mice were examined to determine how these treatments affected ischemic brain injury. By comparison to control mice, mice treated with all doses of a2AP inactivation had significantly smaller areas of brain infarction than control, untreated mice ( Figure 5B ; P<0.001), or TPA-treated mice ( Figure 5B; P<0.001) . In a similar fashion, a2AP-I treated mice had smaller brain hemorrhage than control mice ( Figure 5C ; P<0.05) or TPA-treated mice ( Figure 5C; P<0.001 ). Brain swelling was markedly reduced in mice treated with a2AP-I compared with control mice (Figure 5D ; P<0.001) or with mice treated with TPA ( Figure 5D; P<0.001 ).
Discussion
These data suggest that circulating a2AP has important effects on the dissolution of the culprit MCA thrombus and the development of brain microvascular thrombosis, infarction, blood brain barrier breakdown, hemorrhage, swelling, mortality, and disability after cerebral thromboembolism. Several effects were dose-related because there were significant positive correlations between circulating a2AP levels or activity and the extent of brain infarction, brain swelling, microvascular thrombosis, and MMP-9 expression. Conversely, there was a significant negative correlation between a2AP levels and dissolution of the culprit MCA thrombus. When compared with TPA-treated mice, a2AP-I given late after cerebral thromboembolism had a longer therapeutic window than TPA for protecting against brain injury and hemorrhage.
The finding that increased a2AP levels enhance brain infarction and the resistance of MCA thrombus to dissolution is consistent with clinical observations that a2AP may contribute to stroke in humans. In a case-cohort design, the Atherosclerosis Risk in Communities Study found that elevated a2AP levels were associated with an increased univariate risk of subsequent stroke. 9 Recent studies have noted that genetic deficiency or plasmin-induced deficiency of a2AP reduce brain infarction in nonthrombotic models of focal ischemia induced by temporary or permanent surgical ligation of the MCA. 15, 16, 30 The present findings are also consistent with Figure 5 . Effect of α2-antiplasmin (a2AP) inactivation (a2AP-I) after cerebral thromboembolism on survival, brain infarction, hemorrhage, and swelling. A, Survival in mice treated with no agent (control, Ctl), tissue plasminogen activator (TPA; 10 mg/kg), low dose a2AP-I (9 mg/kg), or high dose a2AP-I (as whole antibody (21.3 mg/kg) or Fab (9.3 mg/kg)) 30 minutes after stroke onset. Mice were observed for 7 days post stroke. Effects of treatment on brain infarction (B), brain hemorrhage (C), and brain swelling (D) after thromboembolism in surviving mice. Survival groups n=12 to 16 in each cohort, data represent means±SE. *P≤0.05, ***P≤0.001, and ****P≤0.0001 vs control or TPA. Control a2AP-I a2AP -/- Figure 4 . Matrix metalloproteinase-9 (MMP-9) expression after middle cerebral artery (MCA) thromboembolism. Representative images of MMP-9 immunofluorescence staining (red) in the ischemic hemispheres of mice with increased a2AP (⇑a2AP), normal a2AP levels (control, Ctl), a2AP deficiency (a2AP −/− ), and mice treated with a2AP inactivation (a2AP-I) or TPA. MMP-9 expression was assessed by double immunofluorescence staining for MMP-9 (DyLight549, red) and collagen IV (DyLight488, green). Representative micrographs with DAPI (4',6diamidino-2-phenylindole)-stained nuclei (blue) were taken using a Zeiss LSM 710 confocal microscope at 40× magnification. Bar graph, quantitative digital analysis of the density of MMP-9 immunofluorescence (immunofluorescence units) of 10 40× fields from each stroke hemisphere. Data represent means±SE of n=4 to 5 mice per group. Line graph, relation between MMP-9 immunofluorescence staining density (units) and a2AP blood levels in mice supplemented with a2AP, normal, and a2AP-deficient mice. *P≤0.05, **P≤0.001, and ***P≤0.001. Bar=50 μm.
recent reports that increased levels of a2AP may contribute to the failure of TPA treatment in humans and in mice. 13, 14 In humans and in mice, thromboembolic occlusion of the MCA is associated with significant ischemic brain injury, edema, hemorrhage, and reduced survival. 31, 32 Consistent with these data, our study showed that proximal MCA thromboembolism had a high mortality. Treatment with an a2AP-I caused a marked reduction in mortality by comparison to TPA and to controls. Examination of surviving mice showed that a2AP-I treatment was associated with reduced hemorrhage and brain swelling, 2 key factors that contribute to mortality after MCA stroke.
In studies designed to examine the dynamics of MCA thrombus dissolution in relation to tissue injury, a2AP levels were inversely proportional to thrombus dissolution measured 6 hours after thromboembolism, which is consistent with previous studies showing that circulating a2AP levels or activity regulate the extent of fibrinolysis. 22, 33, 34 In addition, combined deficiency of thrombus-bound a2AP and circulating a2AP were associated with even greater dissolution of the MCA thromboembolus, than deficiency of circulating a2AP alone, indicating the important role played by thrombus-associated a2AP in this process. 35, 36 Because of its role in fibrinolysis of the MCA thromboembolus, thrombus-bound a2AP may have been expected to affect tissue ischemia, but there was no detectable additional effect on brain infarction and swelling.
By comparison to controls or TPA-treated mice, the reduction of brain bleeding seen in mice treated with a2AP-I is unanticipated because a2AP is often considered to protect against hemorrhage in fibrinolytic states. 10 Because TPA and a2AP-I act in the same pathway to enhance plasmin activity, they may be expected to have similar effects on cerebral thromboembolism. It is notable that TPA therapy caused greater dissolution of the MCA thromboembolus than a2AP-I, but it also caused greater ischemic brain injury, swelling, and death. The mechanisms responsible for the different effects of TPA and a2AP-I are currently unknown, but may be attributable to singular effects of these agents on reperfusion injury, MMP-9 expression, acute inflammation, microvascular thrombosis, neuroprotection, and other factors. Several previous studies suggest that during prolonged ischemia, TPA has neurotoxic effects on the ischemic brain, which include cleavage of the NMDA (N-methyl-Daspartate) receptor, enhancement of excitotoxicity, blood brain barrier breakdown, promotion of apoptosis, and so on. 20, 37 Microvascular thrombosis plays an important role in ischemic stroke because microvascular thrombosis diminishes plasma flow, which accentuates brain injury and is associated with breakdown of the blood brain barrier, hemorrhage, and other complications. 24, [38] [39] [40] Microvascular thrombosis may be triggered initially by exposure of tissue factor, reflecting activation of endothelial cells, leukocytes, or blood brain barrier breakdown. [40] [41] [42] Inhibition of fibrin formation reduces ischemic injury, arguing that it plays a key pathophysiologic role in ischemic stroke; still the role of fibrinolysis in microvascular thrombosis is poorly understood. [40] [41] [42] [43] These data provide the first evidence that levels of a2AP are positively correlated, in a dose-dependent fashion, with the extent of microvascular thrombosis in the ischemic hemisphere. These differences cannot be explained by changes in blood cell populations as the complete blood counts of a2AP +/+ and a2AP −/− mice were similar ( Table I in the online-only Data  Supplement) . Chopp and colleagues postulated that inhibition of fibrinolysis may accentuate microvascular thrombosis in stroke, and studies have shown that microvascular thrombosis induced by endotoxemia is enhanced when fibrinolysis is inhibited. 24, [44] [45] [46] Consistent with that hypothesis, our data shows that differences in a2AP levels, which affect dissolution of the MCA thrombus, also modulate the development of microvascular thrombosis. Still, it is important to note that, despite their common effects on promoting thrombus dissolution through plasmin, TPA accentuated, whereas a2AP-I diminished, microvascular thrombosis. The cause of this difference is unknown, though pharmacological TPA has been shown to have prothrombotic or procoagulant effects after prolonged ischemia. 47 Cerebrovascular ischemia triggers the release of endogenous TPA, which generates plasmin, and plasmin increases brain MMP-9 activity. 20 MMP-9 enhances breakdown of the blood brain barrier, edema, hemorrhage, and apoptosis. 20 Viewed solely as a plasmin inhibitor, circulating a2AP may be expected to have a protective role by reducing MMP-9 activity; conversely, inactivation or deficiency of circulating a2AP may be predicted to be harmful by increasing MMP-9 activity. However, the data suggest the opposite: increased levels of a2AP were associated with significant elevations in MMP-9 expression in the brain, and inactivation of a2AP or a2AP deficiency was associated with reduced MMP-9 expression. Although we did not specifically quantify MMP-9 activation, in situ gelatinase activity followed a similar pattern, and previous studies have shown that MMP-9 expression and activity in ischemic stroke are closely related. 48 Although the exact mechanism remains to be determined, a2AP may increase local MMP-9 levels through ≥3 mechanisms: (1) by enhancing microvascular thrombosis, which increases accumulation of MMP-9-expressing leukocytes, 26, 42 (2) by concentrating MMP-9 at the site through fibrin binding, 50 and (3) by augmenting TPA secretion, 51, 52 which in turn stimulates secretion of MMP-9. 53 Future studies will be necessary to determine the extent to which the harmful effects of a2AP are mediated through acute increases in MMP-9 activity.
In summary, these data suggest that circulating a2AP plays a critical, deleterious role in ischemic neurodegeneration and survival after cerebral thromboembolism by affecting microvascular thrombosis, hemorrhage, MMP-9 expression, swelling, and breakdown of the blood brain barrier. These data add to a growing body of evidence from in vivo models, which suggest that a2AP may have a role in modulating cellular injury and repair beyond its role in fibrinolysis. 15, 21, 33, 54, 55 In this translational model, it is noteworthy that delayed a2AP inactivation after stroke onset reversed the deleterious effects of a2AP to reduce brain injury, bleeding, swelling, disability, and death. By comparison to TPA, the protective effects of a2AP deficiency or inactivation seem to be mediated in part through reductions in microvascular thrombosis and MMP-9 expression. It will be important to better define the fibrinolytic December 2014 and nonfibrinolytic mechanisms responsible for a2AP's effects and to further assess the extent to which therapeutic modulation of a2AP may protect ischemic tissue after thrombotic occlusion.
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